Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 787

1.

Derived neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio may be better biomarkers for predicting overall survival of patients with advanced gastric cancer.

Song S, Li C, Li S, Gao H, Lan X, Xue Y.

Onco Targets Ther. 2017 Jun 26;10:3145-3154. doi: 10.2147/OTT.S138039. eCollection 2017.

2.

Addressing current challenges in cancer immunotherapy with mathematical and computational modelling.

Konstorum A, Vella AT, Adler AJ, Laubenbacher RC.

J R Soc Interface. 2017 Jun;14(131). pii: 20170150. doi: 10.1098/rsif.2017.0150. Review.

3.

Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.

Musella M, Manic G, De Maria R, Vitale I, Sistigu A.

Oncoimmunology. 2017 Apr 5;6(5):e1314424. doi: 10.1080/2162402X.2017.1314424. eCollection 2017. Review.

PMID:
28638743
4.

Immune Checkpoints as a Target for Colorectal Cancer Treatment.

Passardi A, Canale M, Valgiusti M, Ulivi P.

Int J Mol Sci. 2017 Jun 21;18(6). pii: E1324. doi: 10.3390/ijms18061324. Review.

5.

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.

Zhu L, Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Palmisiano ND, Wang M, Jia B, Bayerl M, Schell TD, Hohl RJ, Zeng H, Zheng H.

J Hematol Oncol. 2017 Jun 19;10(1):124. doi: 10.1186/s13045-017-0486-z.

6.

Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy.

Concha-Benavente F, Ferris RL.

Front Pharmacol. 2017 May 30;8:332. doi: 10.3389/fphar.2017.00332. eCollection 2017. Review.

7.

IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours.

Seo H, Jeon I, Kim BS, Park M, Bae EA, Song B, Koh CH, Shin KS, Kim IK, Choi K, Oh T, Min J, Min BS, Han YD, Kang SJ, Shin SJ, Chung Y, Kang CY.

Nat Commun. 2017 Jun 6;8:15776. doi: 10.1038/ncomms15776.

8.

Novel "Elements" of Immune Suppression within the Tumor Microenvironment.

Gurusamy D, Clever D, Eil R, Restifo NP.

Cancer Immunol Res. 2017 Jun;5(6):426-433. doi: 10.1158/2326-6066.CIR-17-0117. Review.

PMID:
28576921
9.

CCR6+ B lymphocytes responding to tumor cell-derived CCL20 support hepatocellular carcinoma progression via enhancing angiogenesis.

He H, Wu J, Zang M, Wang W, Chang X, Chen X, Wang R, Wu Z, Wang L, Wang D, Lu F, Sun Z, Qu C.

Am J Cancer Res. 2017 May 1;7(5):1151-1163. eCollection 2017.

10.
11.

Nanoparticles for Effective Combination Therapy of Cancer.

Jadia R, Scandore C, Rai P.

Int J Nanotechnol Nanomed. 2016;1(1). pii: http://www.opastonline.com/wp-content/uploads/2016/10/nanoparticles-for-effective-combination-therapy-of-cancer-ijnn-16-003.pdf. Epub 2016 Oct 30.

12.

Cancer Immunoprevention and Public Health.

Singh SK, Dorak MT.

Front Public Health. 2017 May 8;5:101. doi: 10.3389/fpubh.2017.00101. eCollection 2017. Review.

13.

Nanomaterial-Enabled Cancer Therapy.

Quader S, Kataoka K.

Mol Ther. 2017 Jul 5;25(7):1501-1513. doi: 10.1016/j.ymthe.2017.04.026. Epub 2017 May 19. Review.

PMID:
28532763
14.

Porphyrin-based cationic amphiphilic photosensitisers as potential anticancer, antimicrobial and immunosuppressive agents.

Malatesti N, Munitic I, Jurak I.

Biophys Rev. 2017 Apr;9(2):149-168. doi: 10.1007/s12551-017-0257-7. Epub 2017 Mar 24. Review.

15.

Nanoparticle Design Strategies for Effective Cancer Immunotherapy.

Velpurisiva P, Gad A, Piel B, Jadia R, Rai P.

J Biomed (Syd). 2017;2(2):64-77. doi: 10.7150/jbm.18877.

16.

Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells.

Liu Y, Liang X, Yin X, Lv J, Tang K, Ma J, Ji T, Zhang H, Dong W, Jin X, Chen D, Li Y, Zhang S, Xie HQ, Zhao B, Zhao T, Lu J, Hu ZW, Cao X, Qin FX, Huang B.

Nat Commun. 2017 May 10;8:15207. doi: 10.1038/ncomms15207.

17.

An Immune Atlas of Clear Cell Renal Cell Carcinoma.

Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H, van den Broek M, Beisel C, Stadler MB, Gedye C, Reis B, Pe'er D, Bodenmiller B.

Cell. 2017 May 4;169(4):736-749.e18. doi: 10.1016/j.cell.2017.04.016.

18.

HO-1 Induction in Cancer Progression: A Matter of Cell Adaptation.

Nitti M, Piras S, Marinari UM, Moretta L, Pronzato MA, Furfaro AL.

Antioxidants (Basel). 2017 May 5;6(2). pii: E29. doi: 10.3390/antiox6020029. Review.

19.

Engineering cancer microenvironments for in vitro 3-D tumor models.

Asghar W, El Assal R, Shafiee H, Pitteri S, Paulmurugan R, Demirci U.

Mater Today (Kidlington). 2015 Dec;18(10):539-553. doi: 10.1016/j.mattod.2015.05.002.

20.

Prognostic effects of preoperative obstructive pneumonitis or atelectasis and comparison with tumor size in non-small cell lung cancer.

Pang Z, Ding N, Dong W, Ni Y, Zhang T, Qu X, Du J, Liu Q.

J Thorac Dis. 2017 Mar;9(3):768-778. doi: 10.21037/jtd.2017.02.88.

Supplemental Content

Support Center